Oxford BioDynamics EpiSwitch Cirt results show clinical utility
(Alliance News) - Oxford BioDynamics PLC on Thursday said it is planning to apply for inclusion into the National Comprehensive Cancer Network clinical guidelines, as it reported the publication of interim results from its FDA-registered Prowes trial. Read More